Corporate ProfileNeos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have three approved ADHD products, two of which use our ODT technology and one of which is an extended-release (ER) oral suspension. Our growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.
- 12/26/18Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
- 11/30/18Neos Therapeutics Announces Realignment of Commercial Organization
- 11/09/18Neos Therapeutics Reports Third Quarter 2018 Financial Results
- 11/06/18Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
Corporate Whistleblower Hotline
Report online: http://www.openboard.info/NEOS/
Call toll-free: (844) 375-8324 (24 hours a day, 7 days a week)
Anytime, from any location. You DO NOT have to give your name.